



Patent Docket P1746R1P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Vanessa Chisholm et al.

Serial No.: 10/714,000

Filed: November 14, 2003

For: EXPRESSION VECTORS AND

METHODS

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

Confirmation No: To Be Assigned

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May <u>14</u>, 2004

Tom Marrs

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[] 37 CFR §1.97(c)

 by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of Filing Date: November 14, 2003

Page 2

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

• after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

	cise explanation of relevance of the items listed on PTO-1449 is: not given			
[]	given for each listed item			
[]	given for only non-English language listed item(s) [Required]			

Serial No.: 10/714,000

Filing Date: November 14, 2003

Page 3

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: May 14, 2004

Alex Andrus, Ph.D.

Reg. No. 44,509

Telephone No. (650) 467-4255

, •	•	MAY		Sheet 1 of 1		
F	ORM PTO-	1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.		
		Patent and Trademark Office	P1746R1P1	10/714,000		
		Adomiesto	Applicant			
l	LIST OF DI	SCLOSURES CHEED BY APPLICANT	Chisholm et al.			
(Use several sheets if necessary)			Filing Date	Group		
			14 Nov 2003	1		
	-	OTHER DISCLOSURES (Including Author, Title, Date,	Pertinent Pages, etc.)			
•	54	Assaraf et al., "Identification of Methotrexate Transport Deficiency in Mammalian Cells Using Fluoresceinated Methotrexate and Flow Cytometry" Proc. Natl. Acad. Sci. USA 84:7154-7158 (Oct 1987)				
į	55	Haber et al., "Properties of an Altered Dihydrofolate Reductase Encoded by Amplified Genes in Cultured Mouse Fibroblasts" <u>Journal of Biological Chemistry</u> 256(18):9501-9510 (1981)				
•	56	Herlitschka et al., "Overexpression of Human Prothrombin in Permanent Cell Lines Using a Dominant Selection/ Amplification Fusion Marker" <u>Protein Expression and Purification</u> 8:358-364 (1996)				
	57	Kaufman et al., "Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus" <u>Nucleic Acids Research</u> 19(16):4485-4490 (1991)				
	58	Page et al., "High Level Expression of the Humanized Monoclonal Antibody Campath-1H in Chinese Hamster Ovary Cells" <u>Bio/Technology</u> 9:64-68 (1991)				

Examiner Date Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.